October 24, 2016
Genotype 5 is the least common hepatitis C subtype, comprising less than 1% of global infections. Nonetheless, it is the most common type of infection in Southern Africa, where it represents more than half of all infections.
Although fewer clinical studies have been conducted with patients who have genotype 5 infection, current guidelines suggest that genotype 5 patients with or without liver damage should start treatment with sofosbuvir/ledipasvir or sofosbuvir/velpatasvir.
Credit: naruedom for iStock via Thinkstock.
Sony Salzman is a freelance journalist reporting on health care and medicine, who has won awards in both narrative writing and radio journalism. Follow Salzman on Twitter: @sonysalz.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals|
|This Week in HIV Research: Another Person Possibly Cured of HIV; and Long-Acting Rilpivirine Suppresses HIV in Rectal Tissue|
|This Week in HIV Research: HIV-Related Inflammation May Be Irreversible; and Genetically Engineered T-Cells Resist HIV|
|How Close Are We to a Cure for HIV? A Q&A With HIV Cure Scientific Superstars|
|Dolutegravir and the Central Nervous System: A Top HIV Clinical Development of 2016|